Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03333941 · ClinicalTrials.gov registry record
Continued Access to the Recell® Device for Treatment of Acute Burn Injuries
A clinical trial, sponsored by Avita Medical.
- Completed
- Registry status
- 76
- Enrollment target
NCT03333941 is a clinical trial that has completed, run by Avita Medical. The registered enrollment target is 76 participants.
The verdict
NCT03333941 has completed, sponsored by Avita Medical.
- COMPLETED
- Registry status
- 76 participants
- Enrollment target
Study Summary
The overall purpose of this continued access study is to allow ongoing treatment of subjects at selected investigational sites while the marketing application for the ReCell® Autologous Cell Harvesting Device is under FDA review. This is a prospective, multicenter, single-arm observational study to evaluate the safety and clinical performance of the ReCell® device when used as an adjunct to meshed autografts in patients with acute thermal burn injuries requiring skin grafting for closure.
Interventions
- DEVICE ReCell® Autologous Cell Harvesting Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2017-10-26 |
| Est. Completion | 2019-05-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03333941
The ClinicalTrials.gov registry entry for NCT03333941 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avita Medical, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ReCell® Autologous Cell Harvesting Device is the first listed.
NCT03333941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03333941 about?
NCT03333941 is a clinical study titled "Continued Access to the Recell® Device for Treatment of Acute Burn Injuries". The overall purpose of this continued access study is to allow ongoing treatment of subjects at selected investigational sites while the marketing application for the ReCell® Autologous Cell Harvesting Device is under FDA review. This is a prospective, multicenter, single-arm observational study to ...
What is the current status of trial NCT03333941?
This trial is currently completed. The enrollment target is 76 participants. The study started on 2017-10-26. Estimated completion is 2019-05-08.
What interventions are being tested in trial NCT03333941?
The interventions under investigation include: ReCell® Autologous Cell Harvesting Device (DEVICE).
Who is sponsoring clinical trial NCT03333941?
This trial is sponsored by Avita Medical, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.